Nirupama S Wijesuriya1, Danny J Eckert1,2, Amy S Jordan3,4, Rachel Schembri3, Chaminda Lewis1, Hailey Meaklim3, Lauren Booker3, Doug Brown5, Marnie Graco3,4, David J Berlowitz6,7,8. 1. Neuroscience Research Australia (NeuRA), Randwick, NSW, Australia. 2. University of New South Wales, Sydney, NSW, Australia. 3. Institute of Breathing and Sleep (IBAS), Melbourne, VIC, Australia. 4. The University of Melbourne, Melbourne, VIC, Australia. 5. Spinal Research Institute, Heidelberg, VIC, Australia. 6. Institute of Breathing and Sleep (IBAS), Melbourne, VIC, Australia. david.berlowitz@austin.org.au. 7. The University of Melbourne, Melbourne, VIC, Australia. david.berlowitz@austin.org.au. 8. Department of Respiratory and Sleep Medicine, Austin Health, Melbourne, VIC, Australia. david.berlowitz@austin.org.au.
Abstract
STUDY DESIGN: Prospective, double-blind, randomised, placebo-controlled, cross-over trial of nasal decongestion in tetraplegia. OBJECTIVES: Tetraplegia is complicated by severe, predominantly obstructive, sleep apnoea. First-line therapy for obstructive sleep apnoea is nasal continuous positive airway pressure, but this is poorly tolerated. High nasal resistance associated with unopposed parasympathetic activation of the upper airway contributes to poor adherence. This preliminary study tested whether reducing nasal decongestion improved sleep. SETTING:Participants' homes in Melbourne and Sydney, Australia. METHODS: Two sleep studies were performed in participants' homes separated by 1 week. Participants were given a nasal spray (0.5 mL of 5% phenylephrine or placebo) in random order and posterior nasal resistance measured immediately. Outcomes included sleep apnoea severity, perceived nasal congestion, sleep quality and oxygenation during sleep. RESULTS:Twelve middle-aged (average (SD) 52 (12) years) overweight (body mass index 25.3 (6.7) kg/m2) men (C4-6, AIS A and B) participated. Nasal resistance was reduced following administration of phenylephrine (p = 0.02; mean between treatment group difference -5.20: 95% confidence interval -9.09, -1.32 cmH2O/L/s). No differences were observed in the apnoea hypopnoea index (p = 0.15; -6.37: -33.3, 20.6 events/h), total sleep time (p = 0.49; -1.33: -51.8, 49.1 min), REM sleep% (p = 0.50; 2.37: -5.6, 10.3), arousal index (p = 0.76; 1.15: -17.45, 19.75), 4% oxygen desaturation index (p = 0.88; 0.63: -23.5, 24.7 events/h), or the percentage of mouth breathing events (p = 0.4; -8.07: -29.2, 13.0) between treatments. The apnoea hypopnoea index did differ between groups, however, all except one participant had proportionally more hypopnoeas than apnoeas during sleep after decongestion. CONCLUSIONS: These preliminary data found that phenylephrine acutely reduced nasal resistance but did not significantly change sleep-disordered breathing severity.
RCT Entities:
STUDY DESIGN: Prospective, double-blind, randomised, placebo-controlled, cross-over trial of nasal decongestion in tetraplegia. OBJECTIVES:Tetraplegia is complicated by severe, predominantly obstructive, sleep apnoea. First-line therapy for obstructive sleep apnoea is nasal continuous positive airway pressure, but this is poorly tolerated. High nasal resistance associated with unopposed parasympathetic activation of the upper airway contributes to poor adherence. This preliminary study tested whether reducing nasal decongestion improved sleep. SETTING:Participants' homes in Melbourne and Sydney, Australia. METHODS: Two sleep studies were performed in participants' homes separated by 1 week. Participants were given a nasal spray (0.5 mL of 5% phenylephrine or placebo) in random order and posterior nasal resistance measured immediately. Outcomes included sleep apnoea severity, perceived nasal congestion, sleep quality and oxygenation during sleep. RESULTS: Twelve middle-aged (average (SD) 52 (12) years) overweight (body mass index 25.3 (6.7) kg/m2) men (C4-6, AIS A and B) participated. Nasal resistance was reduced following administration of phenylephrine (p = 0.02; mean between treatment group difference -5.20: 95% confidence interval -9.09, -1.32 cmH2O/L/s). No differences were observed in the apnoea hypopnoea index (p = 0.15; -6.37: -33.3, 20.6 events/h), total sleep time (p = 0.49; -1.33: -51.8, 49.1 min), REM sleep% (p = 0.50; 2.37: -5.6, 10.3), arousal index (p = 0.76; 1.15: -17.45, 19.75), 4% oxygen desaturation index (p = 0.88; 0.63: -23.5, 24.7 events/h), or the percentage of mouth breathing events (p = 0.4; -8.07: -29.2, 13.0) between treatments. The apnoea hypopnoea index did differ between groups, however, all except one participant had proportionally more hypopnoeas than apnoeas during sleep after decongestion. CONCLUSIONS: These preliminary data found that phenylephrine acutely reduced nasal resistance but did not significantly change sleep-disordered breathing severity.
Authors: Nirupama S Wijesuriya; Laura Gainche; Amy S Jordan; David J Berlowitz; Mariannick LeGuen; Peter D Rochford; Fergal J O'Donoghue; Warren R Ruehland; Jayne C Carberry; Jane E Butler; Danny J Eckert Journal: J Physiol Date: 2018-04-25 Impact factor: 5.182
Authors: Richard B Berry; Rohit Budhiraja; Daniel J Gottlieb; David Gozal; Conrad Iber; Vishesh K Kapur; Carole L Marcus; Reena Mehra; Sairam Parthasarathy; Stuart F Quan; Susan Redline; Kingman P Strohl; Sally L Davidson Ward; Michelle M Tangredi Journal: J Clin Sleep Med Date: 2012-10-15 Impact factor: 4.062
Authors: Danny J Eckert; David P White; Amy S Jordan; Atul Malhotra; Andrew Wellman Journal: Am J Respir Crit Care Med Date: 2013-10-15 Impact factor: 21.405
Authors: Donald E Stull; Eli O Meltzer; John H Krouse; Laurie Roberts; Susan Kim; Lori Frank; Robert Naclerio; Valerie Lund; Aidan Long Journal: Am J Rhinol Allergy Date: 2010 Jan-Feb Impact factor: 2.467
Authors: Enrique Arredondo; Monica DeLeon; Ishimwe Masozera; Ladan Panahi; George Udeani; Nhan Tran; Chi K Nguyen; Chairat Atphaisit; Brooke de la Sota; Gabriel Gonzalez; Eileen Liou; Zack Mayo; Jennifer Nwosu; Tori L Shiver Journal: Medicina (Kaunas) Date: 2022-02-02 Impact factor: 2.430